Since late 2018, the Immune Deficiency Foundation (IDF) has been tracking a troubling shortage of plasma-based immunoglobulin (Ig) products, which are lifesaving, lifelong treatments for people with primary immunodeficiency diseases (PI), specifically those who are antibody deficient.
Our first public communication on this issue was a blog post from January 2019 entitled Immunoglobulin Product Availability Issues: The Sky Is Not Falling but the World Needs More Plasma. It is a good primer on the shortage, the issues driving it and what can be done to help.
IDF has been in touch with stakeholders on all sides of this ongoing issue, including patients, physicians, hospital leadership across the country, pharmaceutical manufacturers, public health officials and leaders from other patient communities impacted by this shortage. We continue to monitor the situation day-to-day and week-to-week and offer guidance and input where we can to make a difference.
We appreciate all of the emails and stories that people living with PI have been sharing with us regarding the shortage. This communication has been valuable in helping us track how widespread and severe the shortage is and also has guided us in our response as this challenging situation for our community continues to evolve. We encourage you to keep the emails and information flowing through Ask IDF. That is the best, most direct way to let us know what’s happening.
In addition, there has been significant media attention of the plasma shortage. IDF has cataloged a chronological list of stories about the issue.
Supply for plasma continues to be tight both in the U.S. and around the world. The single most important, useful thing we can all do is to encourage plasma donation and celebrate plasma donors as the true heroes that they are. Please visit www.donatingplasma.org for more information that you can share with family, friends, coworkers and your social circles both online and in person!
Continue to check back to this page for updates or more information. For information about Ig products, go to www.primaryimmune.org/ig.